InsidersTradesSigma
Follow the LDX stock price and the full management transaction log of the company, a publicly traded company based in Australia. Shares are quoted on the AU market, under the oversight of ASX. Operating in the Health Care sector, LDX has logged 3 insider filings. Market capitalisation: €110.5m. The latest transaction was reported on 18 June 2026 (Purchase). Among the most active insiders: DOUG WARD. Every trade is openly available.
3
Insider Decl.
n/a
Thresholds
€37,613
3 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LDX Strong Buy (bullish), based on 2 analysts. Average price target: A$0.30.
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,575 of 29,063 companies
24.0
score / 100
Value17
Quality31
FCF yld-9.9%
Earn yld-7.6%
EV/EBITDA·
ROE-34%
Gross mgn63%
Net mgn-57%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 June 2026
关于 LDX
LDX 是一家在 XASX 上市的健康和制药公司。它专注于开发创新解决方案以改善患者健康。